Charles River Laboratories Q2 2026 Earnings: Beats Estimates, Raises Outlook

August 5, 2026 · Published August 7, 2026

CRL topped profit and sales forecasts as drug-testing demand stabilized, and it raised its full-year guidance; a one-time divestiture charge caused a small GAAP net loss.

Key takeaways

• Adjusted (non-GAAP) profit and revenue both beat Wall Street estimates, and shares jumped over 12% as investors welcomed signs that demand from drug-testing and drug-development customers is stabilizing after a long slump.
• Revenue was actually down slightly from a year earlier in dollar terms, but on an “organic” basis (stripping out currency swings and the impact of business sales), sales grew for the first time in nearly two years — the strongest such growth since mid-2023.
• Despite the earnings beat, Charles River posted a small net loss under standard accounting rules (GAAP), because it took a roughly $64 million charge tied to selling off its CDMO and Cell Solutions businesses. That one-time item, not the underlying business, drove the loss.
• The Discovery and Safety Assessment unit — which runs preclinical drug-safety testing, the company’s largest segment — logged its best order backlog relative to billings (“book-to-bill”) in nearly four years, with orders picking up from both large pharmaceutical companies and smaller biotech firms.
• Management raised full-year 2026 guidance on multiple fronts: organic revenue growth is now expected to be flat to up 1%, an improvement from a previously forecast decline, and adjusted earnings-per-share guidance rose to $11.15–$11.45 from $10.80–$11.30.
• Executives said they expect profitability to improve further in the second half of 2026, pointing to more than 500 basis points of margin improvement versus the first half, aided by cost discipline and the leaner portfolio following the recent divestitures.
• The trailing-year profitability figures on this page look weak — including a negative net margin — largely because they still include the impact of the divestiture-related charges and other one-time items rather than reflecting the improving underlying trend management described.

Q2 2026 in context

Figures for the quarter ended Jun 2026 and the quarter ended Jun 2025, as reported to the SEC.

How the stock took it

Charles River Laboratories International Inc closed at $234.12 on Aug 4, 2026, the last session before the report, and at $265.51 on Aug 6, 2026, the first session after it — +13.4% across the report.

Closes from the market's daily record. Each figure spans the report date — from the last session that closed before it to the first that closed after — because a company may report before the open or after the close.

Fundamentals

Financial history →

Sources: company report · earnings call